Cargando…
A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection
BACKGROUND: The primary objective of this meta-analytic study was to determine the impact of RSV-IGIV and palivizumab on risk of respiratory syncytial virus (RSV)-related hospitalization. Secondary objectives were to determine if antibody therapy decreases the risk of RSV infection, intensive care a...
Autores principales: | Morris, Shaun K, Dzolganovski, Biljana, Beyene, Joseph, Sung, Lillian |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720977/ https://www.ncbi.nlm.nih.gov/pubmed/19575815 http://dx.doi.org/10.1186/1471-2334-9-106 |
Ejemplares similares
-
Antibody development for preventing the human respiratory syncytial virus pathology
por: Soto, Jorge A., et al.
Publicado: (2020) -
Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
por: O’Hagan, Shaun, et al.
Publicado: (2023) -
The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection
por: Lanari, Marcello, et al.
Publicado: (2013) -
The prevention of respiratory syncytial virus infection
por: Bollani, L, et al.
Publicado: (2014) -
Severe Respiratory Syncytial Virus Infection
por: Kashiwagi, Yasuyo, et al.
Publicado: (2019)